190 results on '"van Lint, M T"'
Search Results
2. DLI after haploidentical BMT with post-transplant CY
3. Systemic lupus erythematosus complicated with thymoma and pure red cell aplasia (PCRA). CR of both complications following thymectomy and allogeneic haematopoietic SCT (HSCT), but persistence of antinuclear antibodies (ANA)
4. DISCONTINUING IMMUNOSUPPRESSIVE THERAPY FOLLOWING AN ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANT (HSCT):A CROSS SECTIONAL ANALYSIS OF 799 PATIENTS, 1 YEAR POST TRANSPLANT: PH-P337
5. UNMANIPULATED HAPLOIDENTICAL TRANSPLANTS FOR ACUTE MYELOID LEUKEMIA (AML) AND REFRACTORY ANEMIA WITH EXCESS BLASTS (RAEB): PH-O126
6. ALLOGENEIC TRANSPLANTS FOR MYELODISPLASTIC SYNDROMES: STRONG REDUCTION OF TRANSPLANT MORTALITY IN RECENT YEARS: PH-O013
7. Sjögrenʼs syndrome associated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treated with autologous and subsequently allogeneic haematopoietic SCT (HSCT)
8. Paternity wishes in long-term survivors after allogeneic hematopoietic SCT. A study of the late effects working party of the EBMT
9. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts: a single Center experience in 488 patients: O383
10. Anti-CD26 monoclonal antibody for the treatment of steroidrefractory acute graft-versus-host disease (SR-GvHD): a report of two prospective studies: O159
11. Standard treatment of acquired SAA in adult patients 18-40 years old with an HLA-identical sibling donor
12. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation
13. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT
14. Risk factors for non-relapse mortality in 287 patients receiving 1288 donor lymphocyte infusions: P1046
15. Unmanipulated haplo-identical bone marrow transplantation (following non-myeloablative conditioning) for advanced Hodgkinʼs lymphoma using post-transplantation cyclophosphamide: P856
16. Acute graft-versus-host disease II-IV in 1465 patients: has outcome improved over the past two decades?: O386
17. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type
18. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients
19. The long-term effect of pubertal development on bone mineral density in patients who underwent HSCT during childhood: O177
20. Secondary malignancies after stem cell transplantation - a long-term follow up study ten years later: 118
21. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD
22. Acute disseminated encephalomyelitis after allogenic bone marrow transplantation. Report of two cases
23. Invasive aspergillosis in allogeneic stem cell transplant recipients from alternative donor: incidence, risk factors and outcome
24. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia
25. Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up
26. Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant
27. Treatment of refractory chronic GVHD with rituximab: a GITMO study
28. Allogeneic hemopoietic stem cell transplants for patients with relapsed acute leukemia: long-term outcome
29. Progenitor cells trapped in marrow filters can reduce GvHD and transplant mortality
30. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT)
31. Thrombotic thrombocytopenic purpura is still an issue after allogeneic haemopoietic stem cell transplantation
32. Increased risk for secondary thyroid carcinoma after haematopoietic stem cell transplantation: an EBMT Late Effect Working Party study
33. High-dose erithropoietin in patients with persistent anaemia after allogeneic bone marrow transplantation
34. Molecular relapse of acute lymphoblastic leukaemia after allogeneic haematopoietic stem cell transplantation can be successfully treated with donor lymphocyte infusions
35. A GITMO randomised trial in steroid refractory acute graft-versus-host disease: 6methylprednisolone with or without anti-thymocyte globulin
36. A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, γ glutamyl transferase, donor type and cell dose
37. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions
38. Refractory Evans' syndrome treated with allogeneic SCT followed by DLI. Demonstration of a graft-versus-autoimmunity effect
39. DLI after haploidentical BMT with post-transplant CY
40. Standard treatment of acquired SAA in adult patients 18–40 years old with an HLA-identical sibling donor
41. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT
42. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type
43. A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, ? glutamyl transferase, donor type and cell dose.
44. Low-dose fractionated total body irradiation (TBI) adversely affects prognosis of patients with leukemia receiving an HLA-matched allogeneic bone marrow transplant from an unrelated donor (UD-BMT).
45. Secondary thyroid carcinoma after allogeneic bone marrow transplantation during childhood.
46. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG).
47. Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM).
48. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin.
49. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study.
50. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.